Keywords: داروهای ضد انعقاد; Monoclonal antibody; Nanoparticle albumin-bound drug; Tyrosine kinase inhibitor; Immunomodulatory drug; Proteasome inhibitor; Cancer therapeutics; Targeted therapy; Nursing care;
مقالات ISI داروهای ضد انعقاد (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: داروهای ضد انعقاد; ASCT; autologous stem cell transplant; CR; complete response; CT; computed tomography; DPd; daratumumab, pomalidomide, and dexamethasone; DRd; daratumumab, lenalidomide, and dexamethasone; DVd; daratumumab, bortezomib, and dexamethasone; ERd; elotuzumab,
Keywords: داروهای ضد انعقاد; Multiple myeloma; Immunomodulatory drug; Proteasome inhibitor;
Keywords: داروهای ضد انعقاد; AH; amyloid heavy chain; AL; amyloid light chain; ASCT; autologous stem cell transplant; ATTR; amyloid transthyretin; B-Dex; bortezomib and dexamethasone; BMDex; bortezomib plus melphalan and dexamethasone; BNP; brain natriuretic peptide; Bor; bortezomib;
Keywords: داروهای ضد انعقاد; Immunomodulatory drug; IMiD; Revlimid; Pomalyst;
Anti-PD-L1 peptide improves survival in sepsis
Keywords: داروهای ضد انعقاد; Therapeutic peptide; Immunomodulatory drug; Programmed cell death-1; Immunosuppression; Sepsis;
Genomic and in silico analyses of CRBN gene and thalidomide embryopathy in humans
Keywords: داروهای ضد انعقاد; ABPST; Brazilian Association of Thalidomide Victims; CRBN; Cereblon; CRL4; cullin RING-like; CtBP; C-terminal binding protein; CUL4A; cullin-4A; DDB1; DNA damage-binding protein 1; EIE; exon-identity element; ESE; exonic splicing enhancer; ESR; exonic spl
Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma
Keywords: داروهای ضد انعقاد; Multiple myeloma; Histone deacetylase; Histone deacetylase inhibitor; Proteasome inhibitor; Immunomodulatory drug; Bortezomib
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
Keywords: داروهای ضد انعقاد; ASCT; autologous stem cell transplantation; CR; complete response; CRAB; elevated calcium, renal insufficiency, anemia, bone disease; FISH; fluorescence in situ hybridization; GEP; gene expression profiling; IMiD; immunomodulatory drug; MGUS; monoclonal g
The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL)
Keywords: داروهای ضد انعقاد; lenalidomide; immunomodulatory drug; B-cell lymphoma; mantle cell lymphoma
Sequential Bortezomib, Dexamethasone, and Thalidomide Maintenance Therapy after Single Autologous Peripheral Stem Cell Transplantation in Patients with Multiple Myeloma
Keywords: داروهای ضد انعقاد; Post-transplant; Proteasome inhibitor; Immunomodulatory drug; IMiD
Derivatives of Dictyostelium differentiation-inducing factors promote mitogen-activated IL-2 production via AP-1 in Jurkat cells
Keywords: داروهای ضد انعقاد; Dictyostelium; Differentiation-inducing factor; DIF; Interleukin-2; Interferon-γ; Jurkat cells; AP-1; Immunomodulatory drug
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
Keywords: داروهای ضد انعقاد; CCT; conventional chemotherapy; CR; complete response; dex; dexamethasone; EFS; event-free survival; FISH; fluorescence in situ hybridization; HDM; high-dose melphalan; IMiD; immunomodulatory drug; ISS; International Staging System; MGUS; monoclonal gammo
Safety and efficacy of lenalidomide (Revlimid®) in recurrent ovarian and primary peritoneal carcinoma
Keywords: داروهای ضد انعقاد; Ovarian cancer; Immunomodulatory drug; Lenalidomide; Revlimid®;
Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement
Keywords: داروهای ضد انعقاد; CR; complete response; FISH; fluorescence in situ hybridization; HSCT; hematopoietic stem cell transplantation; IFM; Intergroupe Français du Myélome; IMiD; immunomodulatory drug; ISS; International Staging System; MP; melphalan and prednisone; MPT; melp